Pharmaceuticals market Switzerland
Now in its 25th edition, this publication appeared as a purely online version in 2018. It is a collection of data and information on a wide variety of aspects of the pharmaceutical market in Switzerland, including key data from Interpharma companies. All individual graphics are available for download.
The global expenditure of the member companies of Interpharma in 2017 amounted to more than 114 billion CHF in research and development (R&D), of which around 7 billion was spent in Switzerland. The major R&D investments are only possible thanks to the large export volume of the pharmaceutical industry. In 2017, pharmaceutical products worth almost 84 billion CHF were exported, which amounts to an increase of 4.3% over the previous year. With an export volume amounting to more than a third of total exports, the pharmaceutical industry was thus an important pillar of Switzerland’s foreign trade. Europe accounts for 52% of all pharmaceutical exports, making it still the most important export destination for pharmaceutical products from Switzerland.
In 2017, the pharma market grew by 4.1% compared with the previous year to around 5.6 billion francs. This constitutes slightly weaker growth than in the previous year. The growth came in particular from the launch of new and innovative medicines, especially for cancer, but also for products to treat autoimmune diseases such as multiple sclerosis.
Healthcare System Switzerland
This publication appears once a year with the latest facts and figures on health indicators, healthcare costs and how they are financed in Switzerland. In addition, all individual graphics are online and available for download.
In its 37th edition, this publication includes the following information: Around 144,000 people in Switzerland live with Alzheimer’s or another form of dementia, yet only a third of cases are diagnosed. The prevalence of dementia increases with age. In the group of 30 to 64-year-olds, the number of patients with dementia stood at around 7000 in 2016, while in the group of 85 to 89-year-olds there were more than 9800 cases in men and 24,700 cases in women. For some years now, a growing number of deaths resulting from dementia have been observed. In 2000, 1526 people died as a result of dementia, while by 2015 the number had risen to more than 4700. Dementia will continue to increase as a result of demographic developments.
SWISS HEALTHCARE AND PHARMACEUTICAL MARKET
This publication is an English “best-of” version of the above two brochures, which is only available online. It shows the structure, links and funding streams of Switzerland’s healthcare system along with the latest statistics on the pharmaceuticals market of Switzerland.